Targeting Nuclear Factor-κB1 With Andrographolide ― Novel Strategy to Inhibit Vascular Lesions and Aneurysm Formation in Abdominal Aortic Aneurysm ―
Abstract
BACKGROUND: Abdominal aortic aneurysm (AAA) is a severe aortic disease with limited pharmacological treatment to prevent its progression. Whether early prevention of aortic lesions inhibits later formation of AAAs remains unclear. Therefore, this study aimed to investigate whether early intervention could prevent aortic lesion progression and AAA formation, and to explore the underlying molecular mechanisms. METHODS AND RESULTS: Genome-wide RNA sequencing of aortas from saline-treated mice and mice treated with angiotensin (Ang: 1,000 ng/kg/min) II via subcutaneously implanted mini-osmotic pumps for 14 or 28 days showed that nuclear factor (NF)-κB signaling contributes to the phenotypic switch and inflammation, and identified Nfkb1 as a potential key gene in vascular smooth muscle cells (VSMCs) for AAA development. Andrographolide (an NF-κB1 inhibitor) was administered via intraperitoneal injection at a dose of 20 mg/kg/day to pre-treat vascular lesions before AAA formation, and transcriptomic and functional studies were performed to explore the underlying mechanisms. In AngII-treated mice, andrographolide significantly attenuated vascular lesions at the early stage (day 14) and reduced AAA formation at later stages of the disease (day 28). Andrographolide also reduced aortic macrophage infiltration, decreased neutrophil recruitment, and suppressed cytokines. Although detailed mechanistic analyses focused on VSMCs due to their structural predominance in early lesions, chromatin immunoprecipitation (ChIP) further demonstrated that NF-κB1 regulates its direct target Krüppel-like factor 4 to induce VSMC dedifferentiation and tumor necrosis factor (TNF)-α to drive inflammation, indicating that NF-κB1 exacerbates inflammation via TNF-α signaling. CONCLUSIONS: Our results demonstrate a previously unrecognized role of vascular lesions in AAA development and progression. Andrographolide pretreatment may be a novel therapeutic approach for AAA.
Related
- Immobilzation‐Induced Muscle Atrophy Exacerbates Vascular Calcification and Abdominal Aortic Aneurysms Through Irisin Downregulation
- RNA Splicing of the REST Gene by SRRM4 in Vascular Smooth Muscle Cells Promotes Abdominal Aortic Aneurysm Development
- Potential role of resveratrol in abdominal cocoon syndrome: targeting inflammation, oxidative stress, and fibrosis via food-derived bioactive compounds resveratrol for treatment of abdominal cocoon syndrome
- Incidental giant subserosal lipoma of the transverse colon with fat necrosis and abscess formation discovered during emergency laparotomy for blunt abdominal trauma: a case report
- Dysregulated Platelet GPIb alpha - VWF Signalling in Abdominal Aortic Aneurysm formation and Progression
BibTeX
@article{wen2026targeting,
title = {{Targeting Nuclear Factor-κB1 With Andrographolide ― Novel Strategy to Inhibit Vascular Lesions and Aneurysm Formation in Abdominal Aortic Aneurysm ―}},
author = {Ying Wen and Xing Fu and Zheng Chen and Jianxiang Wang and Yingying Liu and Yixian Ren and Zefeng Lin and Luhao Liu and Wai Ho Tang},
journal = {Circulation Journal},
year = {2026},
month = sep,
doi = {10.1253/circj.cj-25-0709},
url = {https://www.jstage.jst.go.jp/article/circj/90/10/90_CJ-25-0709/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Targeting Nuclear Factor-κB1 With Andrographolide ― Novel Strategy to Inhibit Vascular Lesions and Aneurysm Formation in Abdominal Aortic Aneurysm ―
AU - Ying Wen
AU - Xing Fu
AU - Zheng Chen
AU - Jianxiang Wang
AU - Yingying Liu
AU - Yixian Ren
AU - Zefeng Lin
AU - Luhao Liu
AU - Wai Ho Tang
PY - 2026
DA - 2026/09/25
JO - Circulation Journal
DO - 10.1253/circj.cj-25-0709
UR - https://www.jstage.jst.go.jp/article/circj/90/10/90_CJ-25-0709/_article
AB - BACKGROUND: Abdominal aortic aneurysm (AAA) is a severe aortic disease with limited pharmacological treatment to prevent its progression. Whether early prevention of aortic lesions inhibits later formation of AAAs remains unclear. Therefore, this study aimed to investigate whether early intervention could prevent aortic lesion progression and AAA formation, and to explore the underlying molecular mechanisms. METHODS AND RESULTS: Genome-wide RNA sequencing of aortas from saline-treated mice and mice treated with angiotensin (Ang: 1,000 ng/kg/min) II via subcutaneously implanted mini-osmotic pumps for 14 or 28 days showed that nuclear factor (NF)-κB signaling contributes to the phenotypic switch and inflammation, and identified Nfkb1 as a potential key gene in vascular smooth muscle cells (VSMCs) for AAA development. Andrographolide (an NF-κB1 inhibitor) was administered via intraperitoneal injection at a dose of 20 mg/kg/day to pre-treat vascular lesions before AAA formation, and transcriptomic and functional studies were performed to explore the underlying mechanisms. In AngII-treated mice, andrographolide significantly attenuated vascular lesions at the early stage (day 14) and reduced AAA formation at later stages of the disease (day 28). Andrographolide also reduced aortic macrophage infiltration, decreased neutrophil recruitment, and suppressed cytokines. Although detailed mechanistic analyses focused on VSMCs due to their structural predominance in early lesions, chromatin immunoprecipitation (ChIP) further demonstrated that NF-κB1 regulates its direct target Krüppel-like factor 4 to induce VSMC dedifferentiation and tumor necrosis factor (TNF)-α to drive inflammation, indicating that NF-κB1 exacerbates inflammation via TNF-α signaling. CONCLUSIONS: Our results demonstrate a previously unrecognized role of vascular lesions in AAA development and progression. Andrographolide pretreatment may be a novel therapeutic approach for AAA.
SN - 1347-4820
SN - 1346-9843
ER -